Skip to content

Study · Observational study · n = 27,996 · 2009

2 results

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.

Dore DD, Seeger JD, Arnold Chan K

Current medical research and opinion1 Apr 2009Cited by 258 (Europe PMC)

PMID19278373 (opens in a new tab)DOI10.1185/03007990902820519 (opens in a new tab)PepBankPUB-19278373
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studySafety outcome

    In patients initiating exenatide, acute pancreatitis occurred in 0.13% during follow-up.

    In plain wordsIn patients who started exenatide, 0.13% developed acute pancreatitis during follow-up.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableAcute pancreatitis incidence
    Study

    n = 27,996

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · up to 1 yearAs given in this study (human).

    Measurements

    Acute pancreatitis incidence
    0.13%
    exenatide

    Source sentences

    Summary
    During follow-up of up to 1 year, acute pancreatitis occurred among 0.13% of patients treated with exenatide and 0.12% of patients treated with sitagliptin.
    3 context sentences
    Summary · context
    There were 27 996 exenatide initiators and 16 276 sitagliptin initiators and approximately equal numbers of matched comparators.
    Summary · context
    The study population was derived from a large US commercial health insurance transaction database using an active drug safety surveillance system (i3 Aperio).
    Summary · context
    Cohorts of exenatide and sitagliptin initiators were each matched to an equal number of metformin or glyburide (met/gly) initiators using propensity scores to reduce confounding in the comparison of outcomes during follow-up.
  2. 02HumanObservational studySafety outcome

    In patients with diabetes, exenatide initiation was linked to comparable pancreatitis risk versus metformin or glyburide initiation.

    In plain wordsIn patients with diabetes, exenatide was linked to similar pancreatitis risk compared with metformin or glyburide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeAcute pancreatitis relative risk
    Study

    n: not reported in source

    Comparator
    Metformin or glyburide initiators
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · up to 1 yearAs given in this study (human).

    Measurements

    Relative risk
    1 ratio
    exenatide versus comparison cohort

    Source sentences

    Summary
    The risk of acute pancreatitis was comparable for initiators of exenatide (RR 1.0; 95% confidence interval (CI) 0.6-1.7) and sitagliptin (RR 1.0; 95% CI 0.5-2.0) relative to the comparison cohorts.
    2 context sentences
    Summary · context
    The study population was derived from a large US commercial health insurance transaction database using an active drug safety surveillance system (i3 Aperio).
    Summary · context
    Cohorts of exenatide and sitagliptin initiators were each matched to an equal number of metformin or glyburide (met/gly) initiators using propensity scores to reduce confounding in the comparison of outcomes during follow-up.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.